|
Industry-Academia Collaborative Mission gets Centre's nod for accelerating discovery research to early development for biopharmaceuticals
|
|
Our Bureau, Mumbai
May 25 , 2017
|
|
|
The Cabinet Committee on Economic Affairs chaired by the Prime Minister
Narendra Modi has given its approval for Industry-Academia Collaborative
Mission for accelerating discovery research to early development for
biopharmaceuticals.
Named as "Innovate in India, empowering
biotech entrepreneurs & accelerating inclusive innovation", it will
be funded by the government of India. The Mission will be implemented
by Biotechnology Industry Research Assistance Council (BIRAC) - a Public
Sector Undertaking of Department of Biotechnology (DBT).
The
Mission Programme would be a Pan-India program. The key focus areas of
the program would aid in preparing India's technological and product
development capabilities in the biopharmaceutical sector to a level that
it is globally competitive over the next 10-15 years and will transform
the health standards of India's population through affordable product
development.
Total project cost to be funded by Government of
India is Rs. 1500 crore for five years. 50% cost for the Mission
Programme will be arranged through the World Bank loan.
For the
implementation, a Programme Management Unit will be set up at BIRAC
which will work as an operational and functional arm that oversees and
monitors program implementation and progress.
The Mission will
focus on development of specific products - vaccines, biotherapeutics,
medical devices and diagnostics; establishment of shared infrastructure
and facilities; building and strengthening domain specific knowledge and
management skills; creating and enhancing technology transfer
capabilities in public and private sector.
The Mission will
provide a holistic and integrated approach to strengthen and support the
entire product development value chain for accelerating the research
leads to product development. This will help not only in immediate
product development addressing public health needs, but will also help
to create an ecosystem which will facilitate development of a continuous
pipeline of products.
The National Biotechnology Development
Strategy 2015-2020 announced by the DBT lays emphasis on making India
ready to meet the challenge of achieving US $100 billion biotech
industry by 2025. The focus is on generation of biotech products,
processes and technologies for affordable and accessible health care,
promoting innovation R&D, establishing India as world class
biomanufacturing hub, and building the required skilled workforce. To
achieve this, it is important to promote industry -academia interface
and enable the start-ups and small and medium enterprises to build
translational innovation research capacities for affordable healthcare
product development.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|